论文部分内容阅读
目的:观察并分析双歧杆菌乳杆菌三联活菌片辅助治疗新生儿高胆红素血症的临床疗效。方法:按照随机方法选择我院82例新生儿高胆红素血症患儿作为观察对象,根据治疗方法进行分对照组接受常规治疗方案,观察组患儿在此基础上采用双歧杆菌乳杆菌三联活菌片进行辅助治疗,比较2组患儿临床治疗效果。结果:观察组患儿治疗总有效率为95.12%,对照组患儿治疗总有效率为78.05%,2组疗效差异明显,具有统计学意义(P<0.05);观察组患儿不良反应发生率为7.32%,明显低于对照组(24.39%),2组差异显著(P<0.05);观察组患儿胆红素下降程度明显优于对照组,2组差异具有统计学意义(P<0.05)。结论:双歧杆菌乳杆菌三联活菌片辅助治疗新生儿高胆红素血症,临床疗效显著。
OBJECTIVE: To observe and analyze the clinical efficacy of Lactobacillus bifidum triple active viable tablet in the treatment of neonatal hyperbilirubinemia. Methods: According to the randomized method, 82 neonates with hyperbilirubinaemia in our hospital were selected as the observation objects. According to the treatment method, the patients in the control group were given routine treatment. The children in the observation group were treated with Lactobacillus bifidum Trials of live bacteria tablets for adjuvant treatment, the clinical efficacy of two groups of children were compared. Results: The total effective rate was 95.12% in the observation group and 78.05% in the control group, the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the observation group (7.32%), which was significantly lower than that of the control group (24.39%). There was significant difference between the two groups (P <0.05). The decrease of bilirubin in the observation group was significantly better than that in the control group ). Conclusion: Bifidobacterium Lactobacillus triple live bacilli tablets adjuvant treatment of neonatal hyperbilirubinemia, clinical efficacy significantly.